Jay A. Levy, MD

---

Additional Websites

• Lab Website

---

Education

Wesleyan University, Middletown, CT, BA, 1960, Biology
Universite de Paris, France, 1961, Regeneration
Columbia University, New York, MD, 1965, Medicine and Virology

---

Professional Experience

• 1965-1966
  Intern in Medicine, Hospital of the University of Pennsylvania
• 1966-1967
  First year resident in Medicine, Hospital of the University of Pennsylvania
• 1967-1970
  Staff Associate,National Cancer Institute, NIH, Bethesda, MD
• 1970-1971
  Second year resident, University of California, San Francisco (UCSF)
• 1971-1972
  Visiting Scientist, Hopital St. Louis (Prof. M. Boiron), Paris; Hopital Paul-Brousse (Dr. G. Mathe), ICIG, Paris
• 1972-1977
  Assistant Professor of Medicine, Research Associate, Cancer Research Institute, University of California San Francisco
• 1978-1979
  Visiting Scientist, Weizmann Institute, Rehovot, Israel (Prof. N. Haran-Ghera); Pasteur Institute, Paris (Prof. F. Jacob)
• 1978-1985
  Associate Professor of Medicine, and Microbiology and Immunology, University of California San Francisco
• 1985-present
  Professor, Dept of Med., Div of Hem/Onc and Research Assoc, Cancer Research Institute, UCSF

---

Selected Publications

1. Liu L, Wang L, Huang L, Siu V, Teque F, Aweeka FT, Levy JA. Nevirapine Inhibits the Anti-HIV Activity of CD8+ Cells. J Acquir Immune Defic Syndr. 2013 Jun 1; 63(2):184-8.
   View on PubMed
2. Kaushik S, Teque F, Patel M, Fujimura SH, Schmidt B, Levy JA. Plasmacytoid Dendritic Cell Number and Responses to Toll-Like Receptor 7 and 9 Agonists Vary in HIV Type 1-Infected Individuals in Relation to Clinical State. AIDS Res Hum Retroviruses. 2013 Mar; 29(3):501-10.
   View on PubMed
3. Ippolito G, Levy JA, Sonnerborg A, Mugusi F, Dianzani F. AIDS and HIV Infection after Thirty Years. AIDS Res Treat. 2013; 2013:731983.
   View on PubMed
4. Sanou MP, De Groot AS, Murphey-Corb M, Levy JA, Yamamoto JK. HIV-1 Vaccine Trials: Evolving Concepts and Designs. Open AIDS J. 2012; 6:274-88.
   View on PubMed
5. Levy JA, Levy Y. HIV infection: what should be considered in approaches for a cure? AIDS. 2012 Nov 13; 26(17):2253-5.
   View on PubMed
6. Levy JA, Autran B, Coutinho RA, Phair JP. 25 Years of AIDS: recording progress and future challenges. AIDS. 2012 Jun 19; 26(10):1187-9.
   View on PubMed
7. Tugizov SM, Herrera R, Veluppillai P, Greenspan D, Soros V, Greene WC, Levy JA, Palefsky JM. Differential transmission of HIV traversing fetal oral/intestinal epithelia and adult oral epithelia. J Virol. 2012 Mar; 86(5):2556-70.
   View on PubMed
8. Killian MS, Levy JA. HIV/AIDS: 30 years of progress and future challenges. Eur J Immunol. 2011 Dec; 41(12):3401-11.
   View on PubMed
9. Liu L, Johnson C, Fujimura S, Teque F, Levy JA. Transfection optimization for primary human CD8+ cells. J Immunol Methods. 2011 Sep 30; 372(1-2):22-9.
   View on PubMed
10. Knox K, Carrigan D, Simmons G, Teque F, Zhou Y, Hackett J, Qiu X, Luk KC, Schochetman G, Knox A, Kogelnik AM, Levy JA. No evidence of murine-like gammaretroviruses in CFS patients previously identified as XMRV-infected. Science. 2011 Jul 1; 333(6038):94-7.
    View on PubMed
11. Levy JA. Virus-host interactions in HIV pathogenesis: directions for therapy. Adv Dent Res. 2011 Apr; 23(1):13-8.
    View on PubMed
12. Meditz AL, MaWhinney S, Allshouse A, Feser W, Markowitz M, Little S, Hecht R, Daar ES, Collier AC, Margolick J, Kilby JM, Routy JP, Conway B, Kaldor J, Levy J, Schooley R, Cooper DA, Altfeld M, Richman D, Connick E. Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. J Infect Dis. 2011 Feb 15; 203(4):442-51.
    View on PubMed
13. Killian MS, Johnson C, Teque F, Fujimura S, Levy JA. Natural suppression of human immunodeficiency virus type 1 replication is mediated by transitional memory CD8+ T cells. J Virol. 2011 Feb; 85(4):1696-705.
    View on PubMed
14. Tugizov SM, Herrera R, Veluppillai P, Greenspan D, Soros V, Greene WC, Levy JA, Palefsky JM. HIV is inactivated after transepithelial migration via adult oral epithelial cells but not fetal epithelial cells. Virology. 2011 Jan 20; 409(2):211-22.
    View on PubMed
15. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science. 2010 Dec 10; 330(6010):1551-7.
    View on PubMed
16. Ndhlovu LC, Sinclair E, Epling L, Tan QX, Ho T, Jha AR, Eccles-James I, Tincati C, Levy JA, Nixon DF, Hecht FM, Barbour JD. IL-2 immunotherapy to recently HIV-1 infected adults maintains the numbers of IL-17 expressing CD4+ T (T(H)17) cells in the periphery. J Clin Immunol. 2010 Sep; 30(5):681-92.
    View on PubMed
17. Yuan L, Ma L, Fan X, Feng Y, Peng H, Zhao Q, Ruan Y, Levy JA, Shao Y. CD8+ cell noncytotoxic antiviral response in long-term HIV-1 infected former blood donors in China. Curr HIV Res. 2009 Jul; 7(4):437-40.
    View on PubMed
18. Levy JA. The unexpected pleiotropic activities of RANTES. J Immunol. 2009 Apr 1; 182(7):3945-6.
    View on PubMed
19. Levy JA. Not an HIV cure, but encouraging new directions. N Engl J Med. 2009 Feb 12; 360(7):724-5.
    View on PubMed
20. Barbour JD, Ndhlovu LC, Xuan Tan Q, Ho T, Epling L, Bredt BM, Levy JA, Hecht FM, Sinclair E. High CD8+ T cell activation marks a less differentiated HIV-1 specific CD8+ T cell response that is not altered by suppression of viral replication. PLoS One. 2009; 4(2):e4408.
    View on PubMed

View on UCSF Profiles